How current maintenance therapy is changing in ovarian cancer and what’s next-Recording

Video Transcription

Video Summary

This webinar discussed the current trends in maintenance therapy for ovarian cancer. The panelists discussed the different options for maintenance therapy and the criteria for choosing the appropriate treatment. The attendees were polled on their preferences for maintenance therapy in different scenarios. The results showed that PARP inhibitors were the preferred choice for the majority of attendees, with a combination of PARP and bevacizumab also being a popular choice. The panelists provided their comments on the results, noting that the choice of maintenance therapy should be based on the patient's individual situation and the available evidence. They also discussed the limitations in prescription and regulatory guidelines that may influence treatment choices. Additionally, the panelists highlighted the importance of clinical trials in exploring new treatment options, such as antibody drug conjugates. Overall, the webinar emphasized the need for personalized treatment plans based on the patient's biomarkers and disease characteristics.

Keywords

webinar

maintenance therapy

ovarian cancer

treatment options

PARP inhibitor

Bevacizumab

clinical trials

trends

panelists

preferences

PARP inhibitors